|
| Reference | Overall survival | aGVHD | Graft failure | Relapse |
|
|
Ruggeri et al. 2002 [3] | Better (missing KIR ligand) | Decrease (missing KIR ligand) | Decrease (missing KIR ligand) | Decrease (missing KIR ligand) |
| Bishara et al. 2004 [6] | Better (KIR match, GVH direction) | increase (donor aKIR) | No effect | No effect |
| Symons et al. 2010 [7] | Better (iKIR mm, D: haplotype B) | No effect | — | Decrease (iKIRmm;
haplotype B: D/R: +/−) myeloid, lymphoid |
| Weisdorf et al. 2012 [8] | No effect | No effect | — | No effect (KIR increase ligand mm) |
| Cook et al. 2004 [9] | Unknown (haplotype A: CMV reactivation ) | Unknown | — | Unknown |
| Hsu et al. 2005 [10] | Better (missing iKIR ligand) | No effect | — | Decrease (AML, MDS, and missing iKIR ligand) |
| Dalva et al. 2006 [11] | Better (aKIR m) | Decrease (iKIR m) | — | Decrease (aKIR m)
Increase (D: haplotype B) |
| McQueen et al. 2007 [5] | Worse (donor but not recipient has haplotype B) | Increase (donor but not recipient has haplotype B, also Bw4) | — | Increase (haplotype B
D/R: +/−)
Decrease (D: 3DL1/3DL2; R: A3/11or Bw4+) |
| Kim et al. 2007 [12] | Better (D: aKIR) | Increase (D: aKIR: 2DS2-4) | — | Decrease (D: aKIR) |
| Giebel et al. 2009 [13] | Decrease (aKIR mm and group C2+) | Increase
(aKIR mm) | — | Increase (aKIR mm) |
| Stringaris et al. 2010 [14] | Better (D: haplotype B) | Unknown | — | Decrease
(D: aKIR or haplotype B) AML |
| Davies et al. 2002 [15] | Worse (missing KIR ligand) myeloid | No effect | No effect | No effect |
| Giebel et al. 2003 [16] | Better (KIR ligand mm) | No effect | Increase (KIR ligand match) | Decrease
(KIR ligand mm) myeloid |
|
Bornhäuser et al. 2004 [17] | No effect | No effect | — | Increase (KIR ligand mm) |
| Schaffer et al. 2004 [18] | Worse (increase infections) | No effect | — | No effect |
| Beelen et al. 2005 [19] | No effect | No effect | Increase (KIR ligand mm) | Decrease (KIR ligand mm) |
| De Santis et al. 2005 [20] | Worse (KIR epitope mm) | Increase
(NK epitope mm) | Worse (NK epitope mm) | — |
| Kröger et al. 2005 [21] | No effect | Not significant | — | Decrease (KIR ligand mm) |
| Farag et al. 2006 [22] | No effect | No effect | No effect | No effect |
| Miller et al. 2007 [23] | — | Increase (KIR ligand mm) | — | Decrease (both KIR ligand and HLA mm) |
| Yabeet al. 2008 [24] | Worse (KIR ligand mm) | Increase (KIR ligand mm; D:2DS2 ) | — | No effect |
| Cooley et al. 2009 and 2010 [25, 26] | Better
(D: haplotype B) | No effect | No effect | Decrease (D: haplotype B) AML but not ALL |
| Gagne 2009 [4] | No effect (D: haplotype B); Decrease (HLA identical, KIR3DL1: D+R− D: KIR3DL1+/3DS1+ R: Bw4+
R: C1 ligand−) | Increase
(HLA I: 2DL5 mm HLA nonI: 2DS1mm)
Decrease
(HLA I: 2DS3 mm,
D: haplotype B) | — | No effect (D: haplotype B)
Increase (D: 3DL1+/3DS1+
R: Bw4−)
Decrease (D: 3DL1+/3DS1+
R: Bw4+) |
| Venstrom et al. 2010 [27] | Better (D: KIR3DS1) | Decrease
(D: KIR3DS1) | — | No effect (D: 3DS1) |
| Brunstein et al. 2009 [28] | Worse (only with RIC) | Increase (KIR ligand mm)(RIC) | — | Decrease (KIR ligand mm) (RIC) |
| Willemze et al. 2009 [29] | Better (KIR ligand mm) | Decrease | — | Decrease (KIR ligand mm) |
|
